| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.9 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |